[Interleukin-4: a new option in the therapy of systemic psoriasis?].
Homey
B
B
Universitäts-Hautklinik, Heinrich Heine-Universität, Duesseldorf. bernhard.homey@uni-duesseldorf.de
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D006801:Humans; D007279:Injections, Subcutaneous; D015847:Interleukin-4 / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D051379:Mice; D010641:Phenotype; D011565:Psoriasis / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors; D014944:World Health Organization
D000276:Adjuvants, Immunologic; D015847:Interleukin-4